UA78673C2 - Use of lactobacillus strains for treating prostate inflammation and benign prostate hyperplasias - Google Patents
Use of lactobacillus strains for treating prostate inflammation and benign prostate hyperplasias Download PDFInfo
- Publication number
- UA78673C2 UA78673C2 UA2002064624A UA2002064624A UA78673C2 UA 78673 C2 UA78673 C2 UA 78673C2 UA 2002064624 A UA2002064624 A UA 2002064624A UA 2002064624 A UA2002064624 A UA 2002064624A UA 78673 C2 UA78673 C2 UA 78673C2
- Authority
- UA
- Ukraine
- Prior art keywords
- strains
- treatment
- vaccines
- prostatitis
- stages
- Prior art date
Links
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 title claims abstract description 14
- 206010061218 Inflammation Diseases 0.000 title abstract description 3
- 241000186660 Lactobacillus Species 0.000 title abstract description 3
- 230000004054 inflammatory process Effects 0.000 title abstract description 3
- 229940039696 lactobacillus Drugs 0.000 title abstract description 3
- 210000002307 prostate Anatomy 0.000 title abstract description 3
- 229960005486 vaccine Drugs 0.000 claims abstract description 26
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 13
- 201000007094 prostatitis Diseases 0.000 claims description 13
- 230000017074 necrotic cell death Effects 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 239000000725 suspension Substances 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 3
- 230000001681 protective effect Effects 0.000 claims description 3
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000012876 topography Methods 0.000 claims 1
- 239000000969 carrier Substances 0.000 abstract description 2
- 239000000546 pharmaceutical excipient Substances 0.000 abstract description 2
- 238000002360 preparation method Methods 0.000 abstract 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- 210000001215 vagina Anatomy 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000003308 immunostimulating effect Effects 0.000 description 4
- 239000004310 lactic acid Substances 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 208000005107 Premature Birth Diseases 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241000705123 Iaria Species 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- VWEWCZSUWOEEFM-WDSKDSINSA-N Ala-Gly-Ala-Gly Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(O)=O VWEWCZSUWOEEFM-WDSKDSINSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241001174911 Iasis Species 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 241001150538 Iria Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241000224526 Trichomonas Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000013507 chronic prostatitis Diseases 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000018773 low birth weight Diseases 0.000 description 1
- 231100000533 low birth weight Toxicity 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 1
- 239000001393 triammonium citrate Substances 0.000 description 1
- 235000011046 triammonium citrate Nutrition 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU9904408A HU227086B1 (en) | 1999-11-25 | 1999-11-25 | Lactobacillus vaccine for treating prostata inflammatory and benign prostata hyperplasia |
| PCT/HU2000/000122 WO2001037862A2 (en) | 1999-11-25 | 2000-11-23 | A vaccine comprising lactobacilli for treating prostate inflammation and benign prostate hyperplasias |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA78673C2 true UA78673C2 (en) | 2007-04-25 |
Family
ID=90014600
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA2002064624A UA78673C2 (en) | 1999-11-25 | 2000-11-23 | Use of lactobacillus strains for treating prostate inflammation and benign prostate hyperplasias |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US20080175865A1 (cs) |
| EP (1) | EP1272216B1 (cs) |
| AT (1) | ATE470452T1 (cs) |
| AU (1) | AU779214B2 (cs) |
| CA (1) | CA2394843C (cs) |
| CZ (1) | CZ302662B6 (cs) |
| DE (1) | DE60044539D1 (cs) |
| DK (1) | DK1272216T3 (cs) |
| EA (1) | EA005198B1 (cs) |
| ES (1) | ES2348591T3 (cs) |
| HU (1) | HU227086B1 (cs) |
| IL (2) | IL149779A0 (cs) |
| PL (1) | PL201804B1 (cs) |
| PT (1) | PT1272216E (cs) |
| RO (1) | RO122760B1 (cs) |
| RS (1) | RS51201B (cs) |
| SI (1) | SI20960B (cs) |
| SK (1) | SK288132B6 (cs) |
| UA (1) | UA78673C2 (cs) |
| WO (1) | WO2001037862A2 (cs) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1723965A1 (en) | 2005-05-18 | 2006-11-22 | Stallergenes Sa | Compositions for antigen-specific induction of immuno-tolerance via oral immunization |
| US9732131B2 (en) | 2006-02-27 | 2017-08-15 | Calviri, Inc. | Identification and use of novopeptides for the treatment of cancer |
| US20110027348A1 (en) | 2007-08-27 | 2011-02-03 | Janos Feher | Composition and method inhibiting inflammation |
| CA3065325A1 (en) | 2017-06-02 | 2018-12-06 | Arizona Board Of Regents On Behalf Of Arizona State University | A method to create personalized cancer vaccines |
| US12025615B2 (en) | 2017-09-15 | 2024-07-02 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods of classifying response to immunotherapy for cancer |
| EP4038222A4 (en) | 2019-10-02 | 2023-10-18 | Arizona Board of Regents on behalf of Arizona State University | METHODS AND COMPOSITIONS FOR IDENTIFYING NEOANTIGENS FOR USE IN THE TREATMENT AND PREVENTION OF CANCER |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH639280A5 (de) * | 1977-12-23 | 1983-11-15 | Solco Basel Ag | Verfahren zur herstellung einer vakzine gegen das trichomonas-syndrom. |
| DE19522472C2 (de) * | 1995-06-21 | 1998-07-02 | Eugen Baumgaertner | Herstellungsverfahren eines Fermentationsproduktes zur Behandlung von Prostataleiden |
| CN1150314C (zh) * | 1997-08-21 | 2004-05-19 | 纽西兰乳品局 | 增强免疫的乳酸菌 |
| IT1298918B1 (it) * | 1998-02-20 | 2000-02-07 | Mendes Srl | Uso di batteri dotati di arginina deiminasi per indurre apoptosi e/o ridurre una reazione infiammatoria e composizioni farmaceutiche |
| IT1306716B1 (it) * | 1999-06-21 | 2001-10-02 | Mendes S U R L | Associazione di batteri lattici e suo uso per la prevenzione e/o iltrattamento terapeutico di infezioni e di stati infiammatori. |
-
1999
- 1999-11-25 HU HU9904408A patent/HU227086B1/hu unknown
-
2000
- 2000-11-23 IL IL14977900A patent/IL149779A0/xx unknown
- 2000-11-23 SK SK738-2002A patent/SK288132B6/sk not_active IP Right Cessation
- 2000-11-23 DK DK00981507.7T patent/DK1272216T3/da active
- 2000-11-23 AT AT00981507T patent/ATE470452T1/de active
- 2000-11-23 UA UA2002064624A patent/UA78673C2/uk unknown
- 2000-11-23 EP EP00981507A patent/EP1272216B1/en not_active Expired - Lifetime
- 2000-11-23 EA EA200200602A patent/EA005198B1/ru not_active IP Right Cessation
- 2000-11-23 SI SI200020063A patent/SI20960B/sl active Search and Examination
- 2000-11-23 PT PT00981507T patent/PT1272216E/pt unknown
- 2000-11-23 CZ CZ20021771A patent/CZ302662B6/cs not_active IP Right Cessation
- 2000-11-23 ES ES00981507T patent/ES2348591T3/es not_active Expired - Lifetime
- 2000-11-23 RO ROA200200663A patent/RO122760B1/ro unknown
- 2000-11-23 PL PL355886A patent/PL201804B1/pl unknown
- 2000-11-23 CA CA2394843A patent/CA2394843C/en not_active Expired - Fee Related
- 2000-11-23 AU AU18741/01A patent/AU779214B2/en not_active Ceased
- 2000-11-23 WO PCT/HU2000/000122 patent/WO2001037862A2/en active IP Right Grant
- 2000-11-23 DE DE60044539T patent/DE60044539D1/de not_active Expired - Lifetime
- 2000-11-23 RS YUP-374/02A patent/RS51201B/sr unknown
-
2002
- 2002-05-21 IL IL149779A patent/IL149779A/en not_active IP Right Cessation
-
2008
- 2008-03-21 US US12/077,780 patent/US20080175865A1/en not_active Abandoned
-
2011
- 2011-03-16 US US13/049,344 patent/US9056073B2/en not_active Expired - Fee Related
-
2015
- 2015-06-10 US US14/735,637 patent/US20160051657A1/en not_active Abandoned
-
2018
- 2018-02-08 US US15/891,620 patent/US20180161414A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wilson | The hazards of immunization | |
| ES2552153T3 (es) | Vacuna neumocócica y usos de la misma | |
| TWI272105B (en) | Cattle reproduction vaccines | |
| JP4718778B2 (ja) | ウエストナイルワクチン | |
| US20180161414A1 (en) | Vaccine comprising lactobacillus strains for treating prostate inflammation and benign prostate hyperplasias | |
| CN105535964B (zh) | 一种具有免疫调节作用的双链聚核苷酸—ε-聚赖氨酸—硫酸聚糖复合物及其制备使用方法 | |
| CN105664152B (zh) | 一种具有免疫调节作用的双链聚核苷酸—ε-聚赖氨酸复合物及其制备使用方法 | |
| JPWO2003009859A1 (ja) | ヒト免疫療法 | |
| JPH04217631A (ja) | 水酸化亜鉛カルシウム、レシチンおよびｐａｏの抗原溶液用アジュバントとしての使用 | |
| Heymann, CS, Kokernot, RH & de Meillon | Wesselsbron virus infections in man | |
| Karsner et al. | Principles of immunology | |
| RU2366455C2 (ru) | Способ получения специфического иммуномодулятора | |
| JP2024529055A (ja) | Ｃｌｏｓｔｒｉｄｉｕｍ ｃｈａｕｖｏｅｉワクチン及び作製方法 | |
| Fenton | XXXVI. Recent Vaccine Therapy in Otolaryngology | |
| CN111698998A (zh) | 生殖道感染的联合治疗和预防 | |
| Rose et al. | A Manual of Surgery for Students and Practitioners | |
| JPH08231422A (ja) | 混合ワクチン | |
| UA125901C2 (uk) | Ешерихіозно-ентерококова інактивована рідка вакцина проти кишкової палички та ентерокока, спосіб її виготовлення та спосіб лікування і профілактики нею | |
| INoUE et al. | Effects of the Endotoxin-Inactivating Agent on the Biological Properties of Bacterial Endotoxin | |
| Cruickshank | Immunisation | |
| MACCARTY | The Journal of Laboratory and Clinical Medicine VOL. VIII | |
| Pijper | Typhus literature | |
| BR122015019697B1 (pt) | composição de vacina para west nile, e uso de plasmídeo com inserções de sequência de dna de vírus west nile na preparação da mesma |